Marrow Therapeutics

Marrow Therapeutics is a Watertown, MA-based genetic medicines company developing bone marrow-targeted therapies for severe blood disorders such as sickle cell disease and beta thalassemia. Its Transferrin Antibody Bioconjugate (TAB) platform uses engineered antibodies against the transferrin receptor to deliver therapeutic payloads directly to bone marrow cells; lead candidate MAR-101, an in vivo antibody-oligonucleotide conjugate in IND-enabling studies, silences BCL11A to reactivate fetal hemoglobin, an approach designed to avoid the safety, manufacturing and accessibility limits of ex vivo gene therapies. Founded by Scion Life Sciences and led by President and CEO Romesh Subramanian, the company launched in November 2026 with $173 million in combined Series A and B funding.

  • Biotechnology
  • Clinical Trials
  • Genomics
  • Healthtech
  • Pharmaceuticals
  • Healthcare & Life Sciences

1

Round

1

Industry

5

Tags

Nov 17, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 17, 2026

    $173M

    Series B

    Led by venBio

    • Spruce Street Capital
    • RTW Investments
    • Surveyor Capital
    • venBio
    • OrbiMed
    • Columbia Threadneedle Investments
    • KKR
    • NEXTBIO MASTER FUND LP
    • Scion Life Sciences
    • Opaleye
    • Affinity Advisors

    Article coming soon.

Pricing

Research Marrow Therapeutics — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Marrow Therapeutics is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational